You are viewing: Europe Nuclear Medicine Market analysis
Part of: Nuclear Medicine Market (Global)

The Europe Nuclear Medicine Market was valued at $1583.7 Million in 2025 and projected to reach to $3132.3 Million by 2030, representing a compound annual growth rate of 14.6%. Europe's nuclear medicine market is positioned for sustained expansion through 2030, driven by aging demographics, increasing healthcare expenditure, and technological advancements in imaging and therapeutic modalities.

Europe Nuclear Medicine Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Europe Nuclear Medicine Market Trends and Insights

  • This growth trajectory reflects Europe's advancing healthcare infrastructure, increasing prevalence of chronic diseases, and rising adoption of diagnostic imaging technologies across the region.
  • Europe's commitment to precision medicine and early disease detection is driving demand for nuclear medicine procedures, particularly in oncology, cardiology, and neurology applications. The European market benefits from strong regulatory frameworks, established reimbursement systems, and significant investment in nuclear medicine facilities.
  • Europe's aging population and the region's focus on improving patient outcomes through advanced diagnostic capabilities are key catalysts for market expansion through 2030.
  • Healthcare providers across Europe are increasingly integrating nuclear medicine into clinical protocols, supported by technological innovations and growing awareness among both physicians and patients..

Key Market Statistics

  • CAGR (2025-2030) 14.6% CAGR
  • Market Size, 2025 ~USD 1583.7 Million
  • Forecast, 2030 ~USD 3132.3 Million
  • Geography Europe

Europe Nuclear Medicine Market Overview

Market Valuation & Growth :

Europe's nuclear medicine market is valued at $1,583.7 million in 2025, with a robust CAGR of 14.6%, projected to reach $3,132.3 million by 2030, nearly doubling in size over the forecast period.

Advanced Healthcare Infrastructure :

Europe's well-established healthcare systems, regulatory frameworks, and investment in medical technology drive widespread adoption of nuclear medicine diagnostics and therapeutic applications across the region.

Chronic Disease Prevalence :

Rising incidence of cancer, cardiovascular diseases, and neurological disorders across European populations increases demand for precision diagnostic imaging and targeted nuclear medicine treatments.

Precision Medicine Commitment :

Europe's strategic focus on precision medicine and personalized healthcare solutions accelerates the integration of nuclear medicine technologies into clinical practice and treatment protocols.

Europe Nuclear Medicine Market Dynamics

  • The region's strong regulatory environment and emphasis on evidence-based medicine support market growth.
  • Key European markets including Germany, France, and the UK are leading adoption of advanced nuclear medicine solutions.
  • Healthcare providers are increasingly investing in cyclotron facilities and radiopharmaceutical production capabilities to meet growing clinical demand and reduce dependency on imports..

Related Ecosystem

Pharmaceuticals

Top Technologies
  • Bioreactors
  • Analytical Testing
  • Bioanalytical Testing Services
  • Cell Counters
  • Data Management Services
Top Companies
  • Merck KGaA
  • Thermo Fisher Scientific Inc.
  • SANOFI
  • NOVARTIS
  • Pfizer Inc.

    Key Takeaways

    • Europe's nuclear medicine market is projected to grow from $1,583.7M (2025) to $3,132.3M (2030) at a 14.6% CAGR.
    • Europe's aging demographic and high prevalence of chronic diseases are primary drivers of nuclear medicine demand.
    • Strong regulatory frameworks and established reimbursement systems in Europe support sustained market growth.
    • Europe's focus on precision medicine and early disease detection is accelerating adoption of advanced nuclear imaging technologies.

    Nuclear Medicine Market Report Scope

    Report Metric Details
    Base Year 2025
    Fastest Growing Segment THERAPEUTIC NUCLEAR MEDICINE (Type)
    Forecast Period 2025–2030
    Growth Rate CAGR of 15.1% from 2025 to 2030
    Largest Segment DIAGNOSTIC NUCLEAR MEDICINE (Type)
    Market Size Base Year (Billions) ~USD 10.4 (2025)
    Revenue Forecast (Billions) ~USD 21.01 (2030)
    Segments Covered Type

    Europe Nuclear Medicine Market Report Segmentation

    1 segment dimensions are covered across the global market.

    By Type

    • Alpha Emitters
    • Beta Emitters
    • Brachytherapy Isotopes
    • Diagnostic Nuclear Medicine
    • F-18
    • Ga-67
    • I-123
    • I-131
    • Lu-177
    • Other Beta Emitters
    • Other Pet Radiopharmaceuticals
    • Other Spect Radiopharmaceuticals
    • Pet Radiopharmaceuticals
    • Ra-223
    • Rb-82
    • Sm-153
    • Spect Radiopharmaceuticals
    • Tc-99M
    • Therapeutic Nuclear Medicine
    • Tl-201
    • Y-90

    REST OF EUROPE: NUCLEAR MEDICINE MARKET, BY END USER, 2023–2030

    Segment20232024202520262027202820292030CAGR (%)
    ACADEMIC & RESEARCH INSTITUTES3843.449.756.965.174.4859714.3
    DIAGNOSTIC & IMAGING CENTERS107.1124.6145168.8196.4228.4265.430816.3
    HOSPITALS236.8271.9312.5359412.3473.2542.8621.614.7
    OTHER END USERS12.514.216.218.420.923.827.130.713.7
    TOTAL394.4454.2523.4603.1694.7799.8920.21057.315.1

    EUROPE: NUCLEAR MEDICINE MARKET, BY END USER, 2023–2030

    Segment20232024202520262027202820292030CAGR (%)
    ACADEMIC & RESEARCH INSTITUTES181.6208.8240.3276.5318.1365.9420.5482.715
    DIAGNOSTIC & IMAGING CENTERS502.7588688.2805.5942.51102.41288.71504.416.9
    HOSPITALS1102.61273.31471.317001963.52266.92615.43013.315.4
    OTHER END USERS57.165.374.885.698112.1128.2146.414.4
    TOTAL18442135.52474.52867.73322.13847.34452.75146.715.8

    Target Audience

    • Medical Device Manufacturers : Require detailed European market data to assess market size, growth potential, and regional demand for nuclear medicine equipment, imaging systems, and diagnostic devices.
    • Pharmaceutical & Radiopharmaceutical Companies : Need market intelligence on European adoption rates, regulatory pathways, and reimbursement landscapes to guide product launches and commercial strategies for nuclear medicine therapeutics.
    • Healthcare Investors & Private Equity : Seek comprehensive market analysis and forecasts to evaluate investment opportunities in European nuclear medicine providers, technology companies, and healthcare infrastructure projects.
    • Hospital & Diagnostic Center Operators : Require market outlook and trend analysis to inform capital expenditure decisions, service expansion plans, and technology adoption strategies for nuclear medicine departments.
    • Healthcare Consultants & Analysts : Need verified market data and regional insights to support client advisory services, competitive benchmarking, and strategic planning initiatives across European healthcare markets.

    Europe vs. other regions

    HowEurope compares to the other 3 regional blocs covered in this market.

    North America
    ~USD 5801.6 Million · 13.6% wtd CAGR ·
    Asia Pacific
    ~USD 2850 Million · 15.9% wtd CAGR ·
    Latin America
    ~USD 513.9 Million · 7.5% wtd CAGR ·
    Middle East & Africa
    ~USD 474.4 Million · 11% wtd CAGR ·

    Countries within Europe - compare and drill down

    Country2025 size (native)
    GermanyUSD 1387 Million
    FranceUSD 873.6 Million
    UKUSD 971.1 Million
    ItalyUSD 471.5 Million
    SpainUSD 386.2 Million

    Country market size visualization

    Germany
    USD 1387 Million
    France
    USD 873.6 Million
    UK
    USD 971.1 Million
    Italy
    USD 471.5 Million
    Spain
    USD 386.2 Million

    Reasons to Buy this Report

    • Market Size & Growth Validation : Obtain precise market valuation data for Europe ($1,583.7M in 2025) with verified CAGR of 14.6%, enabling accurate financial forecasting and investment decision-making for the region.
    • Country-Level Granularity : Access detailed market breakdowns for major European markets including Germany, France, UK, Italy, and Spain, identifying high-growth opportunities and regional variations in adoption rates.
    • Competitive Landscape Intelligence : Understand market dynamics specific to Europe's regulatory environment, reimbursement structures, and competitive positioning to develop targeted market entry or expansion strategies.
    • Strategic Planning & Forecasting : Leverage comprehensive 5-year forecast data (2025-2030) to align product development, manufacturing capacity, and distribution strategies with European market growth trajectories.
    • Investment & Partnership Opportunities : Identify high-potential European markets and growth segments to guide M&A activities, joint ventures, and capital allocation decisions in the nuclear medicine sector.

    Frequently asked questions

    What is the current size of Europe's nuclear medicine market?

    Europe's nuclear medicine market was valued at $1,583.7 million in 2025 and is expected to reach $3,132.3 million by 2030.

    What is the projected growth rate for Europe's nuclear medicine market?

    Europe's nuclear medicine market is projected to grow at a compound annual growth rate (CAGR) of 14.6% from 2025 to 2030.

    What factors are driving growth in Europe's nuclear medicine market?

    Key drivers include Europe's aging population, increasing prevalence of chronic diseases, strong regulatory frameworks, established reimbursement systems, and growing adoption of precision medicine approaches.

    Which medical applications dominate Europe's nuclear medicine market?

    Oncology, cardiology, and neurology are the primary applications driving demand for nuclear medicine procedures across Europe.

    How does Europe's nuclear medicine market compare to global trends?

    Europe's 14.6% CAGR is slightly below the global average of 15.1%, reflecting the region's mature healthcare infrastructure and established market dynamics.

    RESEARCH METHODOLOGY

    This study involved four major activities in estimating the size of the nuclear medicine market. Exhaustive secondary research was done to collect information on the market, peer market, and parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across value chains through primary research. The bottom-up approach was employed to estimate the overall market size. After that, market breakdown and data triangulation were used to estimate the market size of segments and sub-segments.

    Secondary Research

    The secondary research process involved the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, and SEC filings of companies. Some non-exclusive secondary sources include the Organisation for Economic Co-operation and Development (OECD), European Association of Nuclear Medicine (EANM), National Institutes of Health (NIH), World Nuclear Association (WNA), International Atomic Energy Agency (IAEA), Nuclear Regulatory Commission (NRC), Society of Nuclear Medicine and Molecular Imaging (SNMMI), Nuclear Energy Agency (NEA), Australian Nuclear Science and Technology Organisation (ANSTO), Annual Reports, SEC Filings, Investor Presentations, Journals, Publications from Government Sources and Professional Associations, Expert Interviews, and MarketsandMarkets Analysis.

    Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the clinical decision support system market. It was also used to obtain important information about the key players and market classification and segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

    Primary Research

    In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations operating in the clinical decision support system market. The primary sources from the demand side included industry experts, consultants, healthcare providers, hospital administration, and government bodies. Primary research was conducted to validate the market segmentation, identify key players in the market, and gather insights on key industry trends and key market dynamics.

    Breakdown of Primary Interviews

    Nuclear Medicine Market Size, and Share

    Note 1: Others include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.

    Note 2: Tiers of companies are defined on the basis of their total revenue in 2022; Tier 1: >USD 1 billion, Tier 2: USD 500 million to USD 1 billion, and Tier 3: <USD 500 million.

    To know about the assumptions considered for the study, download the pdf brochure

    Report Metric

    Details

    Siemens Healthineers

    Sr.Sales Manager

    Curium

    General Manager

    Cardinal Health

    Product Sales Specialist

    Market Size Estimation

    Both top-down and bottom-up approaches were used to estimate and validate the total size of the nuclear medicine market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

    • The key players in the industry and markets have been identified through extensive secondary research
    • The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research processes
    • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

    Data Triangulation

    After arriving at the overall market size—using the market size estimation processes as explained above—the market was split into several segments and sub-segments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, the data triangulation, and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides, in the provider, payer, and other industries.

    Market Definition

    Radiopharmaceuticals are drugs that contain radionuclide-emitting ionizing radiation and are used in nuclear imaging to diagnose and treat diseases. The nuclear medicine market is bifurcated into diagnostic and therapeutic segments. Radiopharmaceuticals in the diagnostics market are categorized as SPECT and PET, while radiopharmaceuticals in the therapeutics market are categorized as beta emitters, alpha emitters, and brachytherapy isotopes.

    Key Stakeholders

    • Senior Management
    • Finance/Procurement Department
    • R&D Department

    Report Objectives

    • To define, describe, and forecast the nuclear medicine market on the basis of type, application, procedure volume,end user, and region
    • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
    • To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market
    • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
    • To forecast the size of the market segments with respect to four main regions—North America, Europe, the Asia Pacific, and the Rest of the World (RoW)
    • To profile the key players and comprehensively analyze their market shares and core competencies
    • To track and analyze competitive developments such as partnerships, collaborations, agreements, product approval & enhancements, expansions, and acquisitions in the nuclear medicine market

    Available Customizations

    MarketsandMarkets offers the following customizations for this market report:

    • Additional country-level analysis of the nuclear medicine market.
    • Profiling of additional market players (up to 3)

    Get the Full Nuclear Medicine Market Report

    Full forecast, segment splits, and company analysis for all Nuclear Medicine Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status